Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Pierre-Antoine Juge
Variants of Genes Implicated in Type 1 Interferon Pathway and B-Cell Activation Modulate the EULAR Response to Rituximab at 24 Weeks in Rheumatoid Arthritis
RMD Open
Rheumatology
Allergy
Immunology
Related publications
The Interferon Type I Signature Towards Prediction of Non-Response to Rituximab in Rheumatoid Arthritis Patients
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Non-Response to Rituximab Therapy in Rheumatoid Arthritis Is Associated With Incomplete Disruption of the B Cell Receptor Repertoire
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
B Cell Therapy for Rheumatoid Arthritis: The Rituximab (Anti-Cd20) Experience
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Activation of the Type I Interferon Pathway Is Enhanced in Response to Human Neuronal Differentiation
PLoS ONE
Multidisciplinary
Safety of Rituximab in Rheumatoid Arthritis
Reumatismo
Rheumatology
Genetic Polymorphisms in Key Methotrexate Pathway Genes Are Associated With Response to Treatment in Rheumatoid Arthritis Patients
Pharmacogenomics Journal
Molecular Medicine
Genetics
Pharmacology
NK Cell Count as Predictor of Clinical Response in Patients With Rheumatoid Arthritis Treated With Rituximab
Biologics: Targets and Therapy
Oncology
Immunology
Gastroenterology
Pharmacology
Rheumatology
Allergy
Improvements in Clinical Response Between 12 and 24 Weeks in Patients With Rheumatoid Arthritis on Etanercept Therapy With or Without Methotrexate
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
A Combination of Cellular Biomarkers Predicts Failure to Respond to Rituximab in Rheumatoid Arthritis: A 24-Week Observational Study
Arthritis Research & Therapy
